Therefore, we aim to predict molecular features of EGFR‐mutated lung cancer, including the emergence of secondary EGFR‐T790M mutation and the clearance of EGFR ctDNA, by dynamically monitoring STMs during targeted therapy. This evidence concerns the gene EGFR and lung carcinoma.